Pancreatic Cancer Research

Clinical trialNATerminated

Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer

A Clinical Trial Using Electrochemotherapy With Bleomycin for the Treatment of Non-metastatic Unresectable Pancreatic Cancer

NCT03225781↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Stopped earlyLogistic reasons (Other)
Phase
NA
Status
Terminated
Study type
Interventional
Start
1 July 2017
Expected end
21 December 2018
Enrollment
1 participants
Sites
1
Primary outcomes
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Sponsor
Other
Results posted
No
Last update
26 December 2018

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Electrochemotherapy is a type of electroporation that allows the delivery of drugs to the cells through the local creation of pores in the cell membrane. The electric pulses can be applied directly to the neoplastic cells, allowing for the local concentration of a possible chemotherapeutic agent administered through the bloodstream. This technique does not use heat nor other thermal energies and it is performed using special needles/electrodes linked to a generator ("porator"). In this study this technique will be applied on unresectable pancreatic cancer, already submitted to neoadjuvant treatment and still unresectable, through laparotomy. Bleomycin will be the chemotherapeutic agent.

Papers 4